Strides approved for methoxsalen capsules

BANGALORE, India — Strides Arcolab last week received approval from the Food and Drug Administration for methoxsalen capsules USP, 10-mg (soft gelatin capsules).



The drug is used to treat psoriasis, eczema, vitiligo and some cutaneous lymphomas in conjuction with exopsing the skin to UVA light either from lamps or sunlight. It alters the way skin cells receive UVA radiation, helping to clear up the disease.



The market for methoxsalen is approximately $13.6 million in the United States, with no generic player according to IMS data. The product will be manufacturered at the company's facility at Bangalore and will be marketed in the United States by Strides.